| Daiwa's MGN-3 arabinoxylan compound was originally available in Western countries under the Lane Labs brand MGN 3®. However, on July 9th 2004, after a four and a half year court battle with the FDA over illegal marketing claims, a New Jersey District Judge issued a permanent injunction prohibiting Lane Labs from manufacturing, selling or distributing any more of its MGN 3® brand arabinoxylan because, in the Judge's view, they had been selling is as a cancer and HIV treatment - which is only legal for licensed medicines. As a result, MGN 3® suddenly disappeared from US outlets, and hence from all the European outlets that also carried it. This left many thousands of MGN-3 customers, both in Europe and the US, with the impression that the FDA had banned MGN-3 arabinoxylan itself.
Fortunately, this was not the case. The FDA merely banned Lane Labs itself from selling its own MGN 3® branded version of Daiwa Pharmaceutical's MGN-3 because of its irresponsible and illegal marketing. In fact, it continued to allow other outlets to sell what stock they still had of Lane Labs' because the efficacy and safety of the product was never questioned — only Lane Labs' marketing of it.
A few months after ban was imposed on Lane Labs, the company replaced their MGN 3® with a new product branded arabinoxylan supplement product called Noxylane 4®, which they claimed was superior to their original MGN 3®. This is unfortunately marketing hype as, after the injunction against Lane Labs, Daiwa Pharmaceutical stopped supplying them with MGN-3 arabinoxylan. So the arabinoxylan compound in Noxylane 4® is not the patented arabinoxylan compound manufactured by Daiwa, one which is clinically shown to be more effective than any other arabinoxylan supplements on the market (see arabinoxylan comparison).
Our advice, therefore, is to stay clear of Noxylane 4® if you are only interested in Daiwa's premium grade MGN-3, a vastly superior product to other arabinoxylan compounds. |
